Effects of Different Schedules of MPTP Administration on Dopaminergic Neurodegeneration in Mice

Experimental Neurology

Volumn 148, Issue 1, 1997, Pages 288-292

  Bezard, Erwan ^a   Dovero, Sandra ^a   Bioulac, Bernard ^a   Gross, Christian ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; NERVE PROTEIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ADMINISTRATION; ENZYMOLOGY; INTOXICATION; MALE; MOUSE; NERVE CELL; NERVE DEGENERATION; PARKINSON DISEASE; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; MALE; MICE; MPTP POISONING; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE, SECONDARY; TYROSINE 3-MONOOXYGENASE;

EID: 0031262187     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6648     Document Type: Article

References (28)

1. Benazzouz, A., C. Gross, and B. Bioulac. 1992. MPTP-induced hemiparkinsonism in monkeys: Behavioral, mechanographic, electromyographic and immunohistochemical studies. Exp. Brain Res. 90: 116-120.
2. Bezard, E., S. Dovero, B. Bioulac, and C. Gross. 1997. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci. Lett., in press.
3. Bezard, E., C. Imbert, X. Deloire, B. Bioulac, and C. Gross. 1997. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: Evolution of motor symptoms in monkey. Brain Res. [in press]
4. Buck, K. J., and S. G. Amara. 1994. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. USA 91: 12584-12588.
5. Burns, R. S., C. C. Chiueh, S. P. Markey, M. H. Ebert, D. J. Jacobowitz, and I. J. Kopin. 1983. Aprimate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80: 4546-4550.
6. DiMonte, D., S. A. Jewell, G. Ekstrom, M. S. Sandy, and M. T. Smith. 1986. MPTP and MPP+ cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun. 137: 310-315.
7. DiMonte, D., M. S. Sandy, and M. T. Smith. 1987. Increase efflux rather than oxidation is the mechanism of glutathione depletion by MPTP. Biochem. Biophys. Res. Commun. 148: 153-160.
8. Ehringer, H., and O. Hornykiewicz. 1960. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38: 1236-1239.
9. Gash, D. M. 1989. Direct comparison of CNS directed therapies are needed. Neurobiol. Aging 10: 645-646.
10. Gerlach, M., and P. Riederer. 1996. Animal models of Parkin son's disease: An empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103: 987-1041.
11. Gerlach, M., P. Riederer, H. Przuntek, and M. B. H. Youdim. 1991. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208: 273-286.
12. Hassler, R. 1938. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48: 387-476.
13. Heikkila, R. E., and P. Sonsalla. 1991. The MPTP-treated mouse as a model of parkinsonism: How good is it? Neurochem. Int. 20: 299-303.
14. Heikkila, R. E., B. A. Steber, L. Manzino, and P. K. Sonsalla. 1989. Some features of the nigrostriatal neurotoxin MPTP in the mouse. Mol. Chem. Neuropathol. 10: 171-183.
15. Irwin, I., and J. W. Langston. 1985. The selective accumulation of MPP+ in the substantia nigra: A key to neurotoxicity? Life Sci. 36: 207-212.
16. Jackson-Lewis, V., M. Jakowec, R. E. Burke, and S. Przedborski. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269.
17. Javitch, J., and S. H. Snyder. 1985. Uptake of MPP+ by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin MPTP. Eur. J. Pharmacol. 106: 455-456.
18. Kopin, I. J., and S. P. Markey. 1988. MPTP toxicity: Implication for research in Parkinson's disease. Annu. Rev. Neurosci. 11: 81-96.
19. Langston, J. W., L. S. Forno, C. S. Rebert, and I. Irwin. 1984. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1-1,2,3,6,tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292: 390-394.
20. Liu, Y., A. Roghani, and R. H. Edwards. 1992. Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinum. Proc. Natl. Acad. Sci. USA 89: 9074-9078.
21. Marien, M., M. Briley, and F. Colpaert. 1993. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol. 236: 487-189.
22. Nelson, E. L., C. L. Liang, C. M. Sinton, and D. C. German. 1996. Midbrain dopaminergic neurons in the mouse: Computer-assisted mapping. J. Comp. Neurol. 369: 361-371.
23. Rossetti, Z. L., A. Sotgiu, D. E. Sharp, M. Hadjiconstantinu, and N. H. Neff. 1988. MPTP and free radicals in vitro. Biochem. Pharmacol. 37: 4573-4574.
24. Santiago, M., A. Machado, and J. Cano. 1996. Nigral and striatal comparative study of the neurotoxic action of 1-methyl-4-phenylpyridinium ion: Involvement of dopamine uptake system. J. Neurochem. 66: 1182-1190.
25. Schultz, W., A. Studer, G. Jonsson, E. Sundstrüm, and I. Mefford. 1985. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. Neurosci. Lett. 59: 225-232.
26. Shapira, A. H. V. 1994. Evidence for mitochondrial dysfunction in Parkinson's disease - A critical appraisal. Mov. Disord. 9: 125-138.
27. Sonsalla, P. K., and R. E. Heikkila. 1986. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur. J. Pharmacol. 129: 339-345.
28. Sundström, E., A. Fredriksson, and T. Archer. 1990. Chronic neurochemical and behavioral changes in MPTP-lesionned C57BL/6 mice: A model for Parkinson's disease. Brain Res. 528: 181-188.